|
1
|
Oh IH and Reddy EP: The myb gene family in
cell growth, differentiation and apoptosis. Oncogene. 18:3017–3033.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lipsick JS and Wang DM: Transformation by
v-Myb. Oncogene. 18:3047–3055. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Toscani A, Mettus RV, Coupland R, Simpkins
H, Litvin J, Orth J, Hatton KS and Reddy EP: Arrest of
spermatogenesis and defective breast development in mice lacking
A-myb. Nature. 386:713–717. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sala A: B-MYB, a transcription factor
implicated in regulating cell cycle, apoptosis and cancer. Eur J
Cancer. 41:2479–2484. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Iness AN, Felthousen J, Ananthapadmanabhan
V, Sesay F, Saini S, Guiley KZ, Rubin SM, Dozmorov M and Litovchick
L: The cell cycle regulatory DREAM complex is disrupted by high
expression of oncogenic B-Myb. Oncogene. 38:1080–1092. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Musa J, Aynaud MM, Mirabeau O, Delattre O
and Grünewald TG: MYBL2 (B-Myb): A central regulator of cell
proliferation, cell survival and differentiation involved in
tumorigenesis. Cell Death Dis. 8:e28952017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Thorner AR, Hoadley KA, Parker JS, Winkel
S, Millikan RC and Perou CM: In vitro and in vivo analysis of B-Myb
in basal-like breast cancer. Oncogene. 28:742–751. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Long EM, Long MA, Tsirigotis M and Gray
DA: Stimulation of the murine Uchl1 gene promoter by the B-Myb
transcription factor. Lung Cancer. 42:9–21. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Frau M, Ladu S, Calvisi DF, Simile MM,
Bonelli P, Daino L, Tomasi ML, Seddaiu MA, Feo F and Pascale RM:
Mybl2 expression is under genetic control and contributes to
determine a hepatocellular carcinoma susceptible phenotype. J
Hepatol. 55:111–119. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Krakstad C, Tangen IL, Hoivik EA, Halle
MK, Berg A, Werner HM, Ræder MB, Kusonmano K, Zou JX, Øyan AM, et
al: ATAD2 overexpression links to enrichment of B-MYB-translational
signatures and development of aggressive endometrial carcinoma.
Oncotarget. 6:28440–28452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bar-Shira A, Pinthus JH, Rozovsky U,
Goldstein M, Sellers WR, Yaron Y, Eshhar Z and Orr-Urtreger A:
Multiple genes in human 20q13 chromosomal region are involved in an
advanced prostate cancer xenograft. Cancer Res. 62:6803–6807.
2002.PubMed/NCBI
|
|
12
|
Tanner MM, Grenman S, Koul A, Johannsson
O, Meltzer P, Pejovic T, Borg A and Isola JJ: Frequent
amplification of chromosomal region 20q12-q13 in ovarian cancer.
Clin Cancer Res. 6:1833–1839. 2000.PubMed/NCBI
|
|
13
|
Jin Y, Zhu H, Cai W, Fan X, Wang Y, Niu Y,
Song F and Bu Y: B-Myb is up-regulated and promotes cell growth and
motility in non-small cell lung cancer. Int J Mol Sci. 18:8602017.
View Article : Google Scholar
|
|
14
|
Tao D, Pan Y, Jiang G, Lu H, Zheng S, Lin
H and Cao F: B-Myb regulates snail expression to promote
epithelial-to-mesenchymal transition and invasion of breast cancer
cell. Med Oncol. 32:4122015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Borczuk AC, Gorenstein L, Walter KL,
Assaad AA, Wang L and Powell CA: Non-small-cell lung cancer
molecular signatures recapitulate lung developmental pathways. Am J
Pathol. 163:1949–1960. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nakajima T, Yasui K, Zen K, Inagaki Y,
Fujii H, Minami M, Tanaka S, Taniwaki M, Itoh Y, Arii S, et al:
Activation of B-Myb by E2F1 in hepatocellular carcinoma. Hepatol
Res. 38:886–895. 2008.PubMed/NCBI
|
|
17
|
Skotheim RI, Monni O, Mousses S, Fossa SD,
Kallioniemi OP, Lothe RA and Kallioniemi A: New insights into
testicular germ cell tumorigenesis from gene expression profiling.
Cancer Res. 62:2359–2364. 2002.PubMed/NCBI
|
|
18
|
Ren F, Wang L, Shen X, Xiao X, Liu Z, Wei
P, Wang Y, Qi P, Shen C, Sheng W and Du X: MYBL2 is an independent
prognostic marker that has tumor-promoting functions in colorectal
cancer. Am J Cancer Res. 5:1542–1552. 2015.PubMed/NCBI
|
|
19
|
Qin HD, Liao XY, Chen YB, Huang SY, Xue
WQ, Li FF, Ge XS, Liu DQ, Cai Q, Long J, et al: Genomic
characterization of esophageal squamous cell carcinoma reveals
critical genes underlying tumorigenesis and poor prognosis. Am J
Hum Genet. 98:709–727. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Qin H, Li Y, Zhang H, Wang F, He H, Bai X
and Li S: Prognostic implications and oncogenic roles of MYBL2
protein expression in esophageal squamous-cell carcinoma.
OncoTargets Ther. 12:1917–1927. 2019. View Article : Google Scholar
|
|
21
|
Gualdrini F, Corvetta D, Cantilena S,
Chayka O, Tanno B, Raschellà G and Sala A: Addiction of MYCN
amplified tumours to B-MYB underscores a reciprocal regulatory
loop. Oncotarget. 1:278–288. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sala A, Casella I, Bellon T, Calabretta B,
Watson RJ and Peschle C: B-myb promotes S phase and is a downstream
target of the negative regulator p107 in human cells. J Biol Chem.
271:9363–9367. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Arsura M, Introna M, Passerini F,
Mantovani A and Golay J: B-myb antisense oligonucleotides inhibit
proliferation of human hematopoietic cell lines. Blood.
79:2708–2716. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sala A and Calabretta B: Regulation of
BALB/c 3T3 fibroblast proliferation by B-myb is accompanied by
selective activation of cdc2 and cyclin D1 expression. Proc Natl
Acad Sci USA. 89:10415–10419. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang X, Lv QL, Huang YT, Zhang LH and
Zhou HH: Akt/FoxM1 signaling pathway-mediated upregulation of MYBL2
promotes progression of human glioma. J Exp Clin Cancer Res.
36:1052017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sakai N, Kubota Y and Shuin T:
Statistically significant expression of B-myb in clinically
advanced human renal-cell carcinomas. Int J Oncol. 2:419–423.
1993.PubMed/NCBI
|
|
27
|
Nord H, Segersten U, Sandgren J, Wester K,
Busch C, Menzel U, Komorowski J, Dumanski JP, Malmström PU and Díaz
de Ståhl T: Focal amplifications are associated with high grade and
recurrences in stage Ta bladder carcinoma. Int J Cancer.
126:1390–1402. 2010.PubMed/NCBI
|
|
28
|
Zauli G, Voltan R, di Iasio MG, Bosco R,
Melloni E, Sana ME and Secchiero P: miR-34a induces the
downregulation of both E2F1 and B-Myb oncogenes in leukemic cells.
Clin Cancer Res. 17:2712–2724. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liang HB, Cao Y, Ma Q, Shu YJ, Wang Z,
Zhang F, Ye YY, Li HF, Xiang SS, Song XL, et al: MYBL2 is a
potential prognostic marker that promotes cell proliferation in
gallbladder cancer. Cell Physiol Biochem. 41:2117–2131. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cervellera M, Raschella G, Santilli G,
Tanno B, Ventura A, Mancini C, Sevignani C, Calabretta B and Sala
A: Direct transactivation of the anti-apoptotic gene apolipoprotein
J (clusterin) by B-MYB. J Biol Chem. 275:21055–21060. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mao X, Orchard G, Lillington DM,
Russell-Jones R, Young BD and Whittaker SJ: Amplification and
overexpression of JUNB is associated with primary cutaneous T-cell
lymphomas. Blood. 101:1513–1519. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tao D, Pan Y, Lu H, Zheng S, Lin H, Fang H
and Cao F: B-myb is a gene implicated in cell cycle and
proliferation of breast cancer. Int J Clin Exp Pathol. 7:5819–5827.
2014.PubMed/NCBI
|
|
33
|
Martin CM, Astbury K, Kehoe L, O'Crowley
JB, O'Toole S and O'Leary JJ: The use of MYBL2 as a novel candidate
biomarker of cervical cancer. Methods Mol Biol. 1249:241–251. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Calvisi DF, Simile MM, Ladu S, Frau M,
Evert M, Tomasi ML, Demartis MI, Daino L, Seddaiu MA, Brozzetti S,
et al: Activation of v-Myb avian myeloblastosis viral oncogene
homolog-like2 (MYBL2)-LIN9 complex contributes to human
hepatocarcinogenesis and identifies a subset of hepatocellular
carcinoma with mutant p53. Hepatology. 53:1226–1236. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Iltzsche F, Simon K, Stopp S, Pattschull
G, Francke S, Wolter P, Hauser S, Murphy DJ, Garcia P, Rosenwald A
and Gaubatz S: An important role for Myb-MuvB and its target gene
KIF23 in a mouse model of lung adenocarcinoma. Oncogene.
36:110–1121. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Thomas C, Robinson C, Dessauvagie B, Wood
B, Sterrett G, Harvey J and Amanuel B: Expression of proliferation
genes in formalin-fixed paraffin-embedded (FFPE) tissue from breast
carcinomas. Feasibility and relevance for a routine histopathology
laboratory. J Clin Pathol. 70:25–32. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wolter P, Hanselmann S, Pattschull G,
Schruf E and Gaubatz S: Central spindle proteins and mitotic
kinesins are direct transcriptional targets of MuvB, B-MYB and
FOXM1 in breast cancer cell lines and are potential targets for
therapy. Oncotarget. 8:11160–11172. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Diepenbruck M and Christofori G:
Epithelial-mesenchymal transition (EMT) and metastasis: Yes, no,
maybe? Curr Opin Cell Biol. 43:7–13. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang H, Kim JK, Edwards CA, Xu Z,
Taichman R and Wang CY: Clusterin inhibits apoptosis by interacting
with activated Bax. Nat Cell Biol. 7:909–915. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lang G, Gombert WM and Gould HJ: A
transcriptional regulatory element in the coding sequence of the
human Bcl-2 gene. Immunology. 114:25–36. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lee HJ, Lee EK, Seo YE, Shin YH, Kim HS,
Chun YH, Yoon JS, Kim HH, Han MY, Kim CK, et al: Roles of Bcl-2 and
caspase-9 and −3 in CD30-induced human eosinophil apoptosis. J
Microbiol Immunol Infect. 50:145–152. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Grassilli E, Salomoni P, Perrotti D,
Franceschi C and Calabretta B: Resistance to apoptosis in CTLL-2
cells overexpressing B-Myb is associated with B-Myb-dependent bcl-2
induction. Cancer Res. 59:2451–2456. 1999.PubMed/NCBI
|
|
43
|
Levenson VV, Davidovich IA and Roninson
IB: Pleiotropic resistance to DNA-interactive drugs is associated
with increased expression of genes involved in DNA replication,
repair, and stress response. Cancer Res. 60:5027–5030.
2000.PubMed/NCBI
|
|
44
|
Sottile F, Gnemmi I, Cantilena S, D'Acunto
WC and Sala A: A chemical screen identifies the chemotherapeutic
drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in
neuroblastoma. Oncotarget. 3:535–545. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Iida M, Brand TM, Campbell DA, Li C and
Wheeler DL: Yes and Lyn play a role in nuclear translocation of the
epidermal growth factor receptor. Oncogene. 32:759–767. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Fuster O, Llop M, Dolz S, García P, Such
E, Ibáñez M, Luna I, Gómez I, López M, Cervera J, et al: Adverse
prognostic value of MYBL2 overexpression and association with
microRNA-30 family in acute myeloid leukemia patients. Leuk Res.
37:1690–1696. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Raschella G, Cesi V, Amendola R, Negroni
A, Tanno B, Altavista P, Tonini GP, De Bernardi B and Calabretta B:
Expression of B-myb in neuroblastoma tumors is a poor prognostic
factor independent from MYCN amplification. Cancer Res.
59:3365–338. 1999.PubMed/NCBI
|
|
48
|
Astbury K, McEvoy L, Brian H, Spillane C,
Sheils O, Martin C and O'Leary JJ: MYBL2 (B-MYB) in cervical
cancer: putative biomarker. Int J Gynecologic Cancer. 21:206–212.
2011. View Article : Google Scholar
|
|
49
|
Komiya R: Biogenesis of diverse plant
phasiRNAs involves an miRNA-trigger and Dicer-processing. J Plant
Res. 130:17–23. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Calin GA, Dumitru CD, Shimizu M, Bichi R,
Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al:
Frequent deletions and down-regulation of micro- RNA genes miR15
and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad
Sci USA. 99:15524–15529. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M
and Croce CM: Human microRNA genes are frequently located at
fragile sites and genomic regions involved in cancers. Proc Natl
Acad Sci USA. 101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Martinez I, Cazalla D, Almstead LL, Steitz
JA and DiMaio D: miR-29 and miR-30 regulate B-Myb expression during
cellular senescence. Proc Natl Acad Sci USA. 108:522–527. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Martinez I and Dimaio D: B-Myb, cancer,
senescence, and microRNAs. Cancer Res. 71:5370–5373. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wu Z, Huang X, Huang X, Zou Q and Guo Y:
The inhibitory role of Mir-29 in growth of breast cancer cells. J
Exp Clin Cancer Res. 32:982013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Geng GJ, Yang YT, Jiang J, Yu XY and Fa
XE: MicroRNA-30a suppresses non-small-cell lung cancer by targeting
Myb-related protein B. Exp Ther Med. 15:1633–1639. 2018.PubMed/NCBI
|
|
56
|
Li ZB, Chu HT, Jia M and Li L: Long
noncoding RNA LINC01139 promotes the progression of hepatocellular
carcinoma by upregulating MYBL2 via competitively binding to miR-30
family. Biochem Biophys Res Commun. 525:581–588. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Lee YJ, Kang YR, Lee SY, Jin Y, Han DC and
Kwon BM: Ginkgetin induces G2-phase arrest in HCT116 colon cancer
cells through the modulation of bMyb and miRNA34a expression. Int J
Oncol. 51:1331–1342. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Yu Z, Kim J, He L, Creighton CJ, Gunaratne
PH, Hawkins SM and Matzuk MM: Functional analysis of miR-34c as a
putative tumor suppressor in high-grade serous ovarian cancer. Biol
Reprod. 91:1132014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Wang X, Li M, Wang Z, Han S, Tang X, Ge Y,
Zhou L, Zhou C, Yuan Q and Yang M: Silencing of long noncoding RNA
MALAT1 by miR-101 and miR-217 inhibits proliferation, migration,
and invasion of esophageal squamous cell carcinoma cells. J Biol
Chem. 290:3925–3935. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhang Y, Tang X, Shi M, Wen C and Shen B:
MiR-216a decreases MALAT1 expression, induces G2/M arrest and
apoptosis in pancreatic cancer cells. Biochem Biophys Res Commun.
483:816–822. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Chen J and Chen X: MYBL2 is targeted by
miR-143-3p and regulates breast cancer cell proliferation and
apoptosis. Oncol Res. 26:913–922. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Lam EW, Robinson C and Watson RJ:
Characterization and cell cycle-regulated expression of mouse
B-myb. Oncogene. 7:1885–1890. 1992.PubMed/NCBI
|
|
63
|
de Bruin A, Maiti B, Jakoi L, Timmers C,
Buerki R and Leone G: Identification and characterization of E2F7,
a novel mammalian E2F family member capable of blocking cellular
proliferation. J Biol Chem. 278:42041–42049. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Wong JV, Dong P, Nevins JR, Mathey-Prevot
B and You L: Network calisthenics: Control of E2F dynamics in cell
cycle entry. Cell Cycle. 10:3086–3094. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhu W, Giangrande PH and Nevins JR:
Temporal control of cell cycle gene expression mediated by E2F
transcription factors. Cell Cycle. 4:633–636. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Robinson C, Light Y, Groves R, Mann D,
Marias R and Watson R: Cell-cycle regulation of B-Myb protein
expression: Specific phosphorylation during the S phase of the cell
cycle. Oncogene. 12:1855–1864. 1996.PubMed/NCBI
|
|
67
|
Mowla SN, Lam EW and Jat PS: Cellular
senescence and aging: The role of B-MYB. Aging Cell. 13:773–779.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Inoue K and Fry EA: Novel molecular
markers for breast cancer. Biomark Cancer. 8:25–42. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Lam EW, Bennett JD and Watson RJ:
Cell-cycle regulation of human B-myb transcription. Gene.
160:277–281. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Lam EW and Watson RJ: An E2F-binding site
mediates cell-cycle regulated repression of mouse B-myb
transcription. EMBO J. 12:2705–2713. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Lukas J, Petersen BO, Holm K, Bartek J and
Helin K: Deregulated expression of E2F family members induces
S-phase entry and overcomes p16INK4A-mediated growth suppression.
Mol Cell Biol. 16:1047–1057. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Sala A, Saitta B, De Luca P, Cervellera
MN, Casella I, Lewis RE, Watson R and Peschle C: B-MYB
transactivates its own promoter through SP1-binding sites.
Oncogene. 18:1333–1339. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Müller H, Bracken AP, Vernell R, Moroni
MC, Christians F, Grassilli E, Prosperini E, Vigo E, Oliner JD and
Helin K: E2Fs regulate the expression of genes involved in
differentiation, development, proliferation, and apoptosis. Genes
Dev. 15:267–285. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Infante A, Laresgoiti U, Fernandez-Rueda
J, Fullaondo A, Galán J, Díaz-Uriarte R, Malumbres M, Field SJ and
Zubiaga AM: E2F2 represses cell cycle regulators to maintain
quiescence. Cell Cycle. 7:3915–3927. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Joaquin M and Watson RJ: Cell cycle
regulation by the B-Myb transcription factor. Cell Mol Life Sci.
60:2389–2401. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Santilli G, Schwab R, Watson R, Ebert C,
Aronow BJ and Sala A: Temperature-dependent modification and
activation of B-MYB: Implications for cell survival. J Biol Chem.
280:15628–15634. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Zhu W, Giangrande PH and Nevins JR: E2Fs
link the control of G1/S and G2/M transcription. EMBO J.
23:4615–4626. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Fan X, Wang Y, Jiang T, Cai W, Jin Y, Niu
Y, Zhu H and Bu Y: B-Myb mediates proliferation and migration of
non-small-cell lung cancer via suppressing IGFBP3. Int J Mol Sci.
19:14792018. View Article : Google Scholar
|
